2022
Nicotine Pharmacology, Abuse, and Addiction
Miller M, Picciotto M. Nicotine Pharmacology, Abuse, and Addiction. 2022, 4083-4101. DOI: 10.1007/978-3-030-88832-9_157.ChaptersTobacco useDrugs of abuseNeuropsychiatric disordersGreat public health relevanceGreat public health concernMesolimbic dopamine systemPre-clinical studiesPublic health concernPublic health relevanceNicotinic acetylcholine receptorsIonotropic neurotransmitter receptorsPrimary psychoactive componentSubstantial health risksNicotine exposureNicotine actsSustained tobacco useNicotine pharmacologyRewarding effectsNicotine addictionDopamine systemNervous systemNeurotransmitter receptorsNicotine useAcetylcholine receptorsAddictive propertiesAnimal Models to Investigate the Impact of Flavors on Nicotine Addiction and Dependence
Bagdas D, Kebede N, Zepei AM, Harris L, Minanov K, Picciotto MR, Addy NA. Animal Models to Investigate the Impact of Flavors on Nicotine Addiction and Dependence. Current Neuropharmacology 2022, 20: 2175-2201. PMID: 35611777, PMCID: PMC9886843, DOI: 10.2174/1570159x20666220524120231.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2019
Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus: Mechanisms Related to Nicotine’s Effects on Food Intake
Calarco CA, Picciotto MR. Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus: Mechanisms Related to Nicotine’s Effects on Food Intake. Nicotine & Tobacco Research 2019, 22: 152-163. PMID: 30690485, PMCID: PMC7297099, DOI: 10.1093/ntr/ntz010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsFood intakeNicotinic acetylcholine receptorsWeight gainBody weightPreclinical workAcetylcholine receptorsPost-cessation weight gainOrexigenic agouti-related peptideAnorexigenic proopiomelanocortin (POMC) neuronsNicotine replacement therapyAgouti-related peptideNicotinic agonist cytisineAbility of nicotineLower body weightProopiomelanocortin neuronsNicotine administrationHypothalamic circuitsReplacement therapyArcuate nucleusNicotine effectsNicotine actsAgonist cytisineAverage weight gainTobacco useRodent models
2017
Access to nicotine in drinking water reduces weight gain without changing caloric intake on high fat diet in male C57BL/6J mice
Calarco CA, Lee S, Picciotto MR. Access to nicotine in drinking water reduces weight gain without changing caloric intake on high fat diet in male C57BL/6J mice. Neuropharmacology 2017, 123: 210-220. PMID: 28623168, PMCID: PMC5544033, DOI: 10.1016/j.neuropharm.2017.06.012.Peer-Reviewed Original ResearchConceptsHigh-fat dietCaloric intakeWeight gainFat dietFemale miceMale miceBody weightAdipose tissueEffects of HFDOverall caloric intakeAmphetamine-regulated transcriptNicotinic acetylcholine receptor subunitsLower body weightMelanin-concentrating hormoneSex-dependent mannerRegulation of agoutiChow-fed animalsAcetylcholine receptor subunitsNicotine administrationChronic consumptionArcuate nucleusNicotine dosesNicotine intakeFood intakeTobacco use
2016
Nicotine Pharmacology, Abuse, and Addiction
Miller M, Picciotto M. Nicotine Pharmacology, Abuse, and Addiction. 2016, 3659-3677. DOI: 10.1007/978-1-4939-3474-4_157.ChaptersTobacco useDrugs of abuseNeuropsychiatric disordersGreat public health relevanceGreat public health concernMesolimbic dopamine systemPre-clinical studiesPublic health concernPublic health relevanceNicotinic acetylcholine receptorsIonotropic neurotransmitter receptorsPrimary psychoactive componentSubstantial health risksNicotine exposureNicotine actsSustained tobacco useNicotine pharmacologyRewarding effectsNicotine addictionDopamine systemNervous systemNeurotransmitter receptorsNicotine useAcetylcholine receptorsAddictive properties
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomenNicotine Pharmacology, Abuse, and Addiction
Miller M, Picciotto M. Nicotine Pharmacology, Abuse, and Addiction. 2015, 1-19. DOI: 10.1007/978-1-4614-6434-1_157-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTobacco useDrugs of abuseNeuropsychiatric disordersGreat public health relevanceGreat public health concernMesolimbic dopamine systemPre-clinical studiesPublic health concernPublic health relevanceNicotinic acetylcholine receptorsIonotropic neurotransmitter receptorsPrimary psychoactive componentSubstantial health risksNicotine exposureNicotine actsSustained tobacco useNicotine pharmacologyRewarding effectsNicotine addictionDopamine systemNervous systemNeurotransmitter receptorsNicotine useAcetylcholine receptorsAddictive properties
2013
High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness
Lewis AS, Picciotto MR. High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness. Psychopharmacology 2013, 229: 477-485. PMID: 23624811, PMCID: PMC3766461, DOI: 10.1007/s00213-013-3126-5.Peer-Reviewed Original ResearchConceptsPsychiatric illnessNicotinic acetylcholine receptor expressionPre-clinical animal modelsMultiple psychiatric illnessesChronic nicotine exposureHigh-affinity nAChRsAcetylcholine receptor expressionNicotinic receptor subtypesNovel therapeutic agentsHuman psychiatric illnessCholinergic dysfunctionClinical featuresNicotine exposurePatient populationCholinergic systemNicotine intakeReceptor expressionReceptor subtypesMood disordersTobacco usePharmacological agentsAnimal modelsPsychiatric diseasesAcetylcholine receptorsIllness